Defining the role of Skeletal Muscle SIRT3 in modulation of PH-HFpEF
Description: Pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) is the most common cause of PH worldwide, affecting approximately 1.5 million patients with heart failure in the United States. It is also an increasingly recognized clinical complication of metabolic syndrome. At present, there are no proven effective therapies available for PH-HFpEF, primarily due to the fact that biomolecular pathways regulating this disease are poorly defined and understood. Recently, we found convincing evidence for a mechanism in which sirtuin-3 (SIRT3), the primary mitochondrial deacetylase, is down-regulated in humans and in a rat model of PH-HFpEF. Interestingly, SIRT3 is not dysregulated in the lung or heart, but in the skeletal muscle, with changes in activation associated with increases in pulmonary pressures and vascular remodeling. In the current proposal we hypothesize that skeletal muscle SIRT3 activation mediates the therapeutic effects of nitrite and metformin on PH-HFpEF and metabolic syndrome. Our published data show that restoration of SIRT3 in skeletal muscle with nitrite and metformin therapies improves metabolic syndrome and reduces disease phenotypes via activation of AMPK and glucose transporter 4 (GLUT4). Our unpublished preliminary data show that skeletal muscle activation of SIRT3 drives secretion of myokine FGF21, which in turn inhibits pulmonary artery smooth muscle cells (PASMCs) proliferation and confers systemic benefits on insulin resistance in an AMPK-dependent manner. We have recently generated skeletal muscle-specific SIRT3 knock-out mice (SIRT3SKM-/-). Together with the validated high-fat diet mouse model of PH-HFpEF, we will evaluate the impact of skeletal muscle SIRT3 deficiency, and the effects of treatment with nitrite and metformin, as well as recombinant FGF21 protein, in SIRT3SKM-/- mice. In addition, we will investigate the mechanism by which skeletal muscle SIRT3-mediated FGF21 secretion modulates pulmonary vasculature in PH-HFpEF. This will be performed using in vitro model of PASMCs with recombinant FGF21 protein, FGF21 blockade delta-N17, and conditioned media collected from cultured skeletal muscle cells. We expect that successful execution of the proposed research plan would provide novel mechanistic understanding of PH-HFpEF and identify skeletal muscle SIRT3, together with its downstream myokine effectors, as potential therapeutic targets in the management of PH-HFpEF.
Funder: American Heart Association
Amount: $231,000
Funding type: fellowship
Funder scheme: Scientist Development Grant
Start date: 2017-01-01
End date: 2019-12-31
Investigator: Yen Chun Lai (lead)
Institutions: Indiana University Indianapolis, Indiana University, Indianapolis
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Funded outputs count: 6
Funder award ID: 17SDG33400233
OpenAlex ID: G5359237620
